Journal article
Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial
Abstract
HER2 gene amplification and topoisomerase IIα gene (TOP2A) alteration have been associated with increased benefit from anthracycline compared to non-anthracycline containing adjuvant breast cancer chemotherapy in some but not other studies. Chromosome 17 centromere (CEP17) duplication was measured on TMAs from formalin-fixed paraffin-embedded specimens obtained from 639 of 716 premenopausal women with node positive breast cancer who received …
Authors
Pritchard KI; Munro A; O’Malley FP; Tu D; Li X; Levine MN; Shepherd L; Chia S; Bartlett JMS
Journal
Breast Cancer Research and Treatment, Vol. 131, No. 2, pp. 541–551
Publisher
Springer Nature
Publication Date
1 2012
DOI
10.1007/s10549-011-1840-4
ISSN
0167-6806